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Abstract: Toxicity caused by the exposure to human-made chemicals and environmental conditions
has become a major health concern because they may significantly increase the formation of reactive
oxygen species (ROS), negatively affecting the endogenous antioxidant defense. Living systems
have evolved complex antioxidant mechanisms to protect cells from oxidative conditions. Although
oxidative stress contributes to various pathologies, the intake of molecules such as polyphenols,
obtained from natural sources, may limit their effects because of their antioxidant and antimicrobial
properties against lipid peroxidation and against a broad range of foodborne pathogens. Ingestion of
polyphenol-rich foods, such as fruits and vegetables, help to reduce the harmful effects of ROS, but the
use of supramolecular and nanomaterials as delivery systems has emerged as an efficient method to
improve their pharmacological and therapeutic effects. Suitable exogenous polyphenolic antioxidants
should be readily absorbed and delivered to sites where pathological oxidative damage may take
place, for instance, intracellular locations. Many potential antioxidants have a poor bioavailability,
but they can be encapsulated to improve their ideal solubility and permeability profile. Development
of effective antioxidant strategies requires the creation of new nanoscale drug delivery systems to
significantly reduce oxidative stress. In this review we provide an overview of the oxidative stress
process, highlight some properties of ROS, and discuss the role of natural polyphenols as bioactives
in controlling the overproduction of ROS and bacterial and fungal growth, paying special attention
to their encapsulation in suitable delivery systems and to their location in colloidal systems where
interfaces play a crucial role.




Oxidative stress has been closely associated to the development of pathogenesis and
a large variety of diseases [1–5]. Particularly, the overproduction of reactive oxygen and
nitrogen species (ROS and RNS, respectively) has been frequently evoked as the main cause
of various diseases, including age-related and metabolic disorders, cancer, diabetes, and
cardiovascular diseases, among others [1,3,6,7]. At the chemical level, the term ROS and
RNS refer to a group of short-living radical and non-radical species with different chemical
reactivity, produced by the action of oxygen inside and outside of cells. At the enzymatic
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level, species such as those of superoxide dismutases (SOD), catalases, peroxiredoxins,
sulfiredoxins, and glutathione peroxidases are also involved in the formation of ROS that
can be harmful if not properly controlled [7,8]. Table 1 collects some of the most common
ROS and RNS. For the sake of simplicity, only the reactions with reactive oxygen species
(ROS) are reviewed here.
Table 1. Main radical and non-radical reactive oxygen and nitrogen species (ROS and RNS, respectively).
ROS RNS
Free Radicals Non-Radicals Free Radicals Non-Radicals
Hydroxyl (HO•) Hydrogen peroxide (H2O2) Nitric Oxide (NO•) Dinitrogen trioxide (N2O3)
Superoxide anion (O2•−) Singlet oxygen (1O2) Nitrogen dioxide (NO2•) Dinitrogen tetraoxide (N2O4)
Lipid peroxyl (ROO•) Ozone (O3) Peroxynitrite (ONOO−)
Thiyl (•RS) Lipid peroxide (ROOH) Nitrosothiols (SNOs)
ROS can be produced as a metabolic by-product and, when in low concentrations, they
have been proved to be necessary and beneficial, due to their signaling effects [1,3,9–11].
When in higher concentrations, ROS can lead to a significant modification of the cellular
redox homeostasis, leading to a redox imbalance, which has detrimental consequences
on human health. For example, an excess of •OH radicals and ONOO- can produce lipid
oxidation, damaging cell membranes and lipoproteins, as seen in Figure 1. However,
the changes in the cellular redox equilibria cannot explain, by themselves, the overall
consequences of the oxidative stress. Thus, a full rationalization of oxidative stress’ effects
need to incorporate aspects including the chemical nature of the ROS, their location in
tissues, the kinetics of their formation and degradation, the time of exposure, and the
quantitative detection of increases or decreases in ROS levels [5,9].
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Figure 1. itr en species (ROS and RNS) generation within a cell, and standard
redox potentials (pH = 7) for the redox couples involved in the formation of some ROS, and in their
inhibition, by radical scavengers [8]. CAT: catalase, SOD: superoxide dismutase, GPX: glutathione
peroxidase, NADPH oxidase: nicotinamide adenine dinucleotide phosphate oxidase.
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ROS are formed through electron-transfer reactions whose redox potentials, Ep0,
depend on their environmental conditions. Molecular oxygen is a poor univalent electron
acceptor (ergo a poor oxidant), with a redox potential of −0.16 V (referred to the standard
state of [O2] = 1 M and pH 7) [1]. The addition of electrons leads to the formation of
a number of oxygen-centered radicals and oxygen-centered nonradicals [2,3], and the
one-electron redox potentials in water of some ROS are given in Figure 1 [4].
Tables 2 and 3 show the broad range of reactivities of ROS, which are closely linked to
their redox potential values, Figure 1, due to the low activation energies of the reactions;
meanwhile, those of the non-radical ROS are much slower, and depend on the activation
energy values. In cellular systems, ROS diffuse to different extents and estimations of the
distance they travel prior to reacting contribute to understanding their effects. This distance
can be estimated by considering the relationship between the mean square displacement
of the various ROS species, their diffusion coefficients, and their lifetimes τ (Einstein
equation) [8]. Estimated travel distances suggest that •OH radicals have short half-lives
in solution (t1/2 = 10−9s, Table 1) and react with nonspecific targets at a distance of a few
nanometers, meanwhile H2O2 or O2•− may spread a few tens of micrometers, exerting a
longer range of effect. Further information on the chemical properties of ROS, together
with thermodynamic and kinetic data, can be found elsewhere [8] and in references therein.
Table 2. Half-lives and typical rate constant kexp values of some ROS. L = linolenic acid.
Data from ref. [8].








Table 3. Values of the rate constants for the reaction of ROS with some fatty acids and amino acids.
Data from refs. [12–14].
Rate Constant Values (M−1 s−1) for Reactions of ROS with Fatty Acids (H-Abstraction)
Oleic Linoleic Linolenic
HO• ~109 9 × 109 7.3 × 109
RO• 3.3 × 106 8.8 × 106 1.3 × 107
ROO• 1.1 60 120
O2•− ~0 ~0 <1
HOO• ~0 1.1 × 103 1.7 × 103
1O2 7.5 × 102 9.7 × 103 1.2 × 104
Rate Constant Values (M−1 s−1) for the Reaction of ROS with Aminoacids
Histidine Tyrosine Cysteine Methionine
HO• 4.8 × 109 1.3 × 1010 1.9 × 1010 7.4 × 109
O2•− ~1 ~24 ~0.4 ~0.33
1O2 4.6 × 107 1.3 × 107 5.0 × 107 1.3 × 107
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To control for the redox imbalance by reducing ROS levels, radical scavengers as
antioxidants (AOs) are a feasible systematic treatment, as they are not expected to have any
possible side effects [3,8,15,16]. Polyphenolic antioxidants are widely used in preventive
medicine and a number of cohort and human epidemiological studies suggest that there is
an inverse relationship between polyphenol intake and antioxidant levels, which is usually
associated with the routinely intake of polyphenol-rich foods [1,4,15,17–20].
1.2. Physiological Functions of ROS
It was believed for a long time that an increase in the formation of ROS was closely
associated to oxidative stress, representing an unavoidable biochemical problem associ-
ated to aerated life, that can be somehow prevented through a systematic antioxidant
treatment [1–3,6,7]. This misconception is usually associated to the incorrect assumption
that ROS has no physiological functions, but only react with relevant tissues and cell
components with harmful effects [1]. ROS are now considered not necessarily as unsafe
or dangerous, molecules but rather as essential signaling messengers. The distinction
between the beneficial and detrimental effects of ROS is difficult and not always clear, but
a good starting point can by considering the nature of the ROS that are formed, and how
they are formed (physiological or non-physiological) in different cellular and subcellular
compartments [4,9–11,21,22].
It is commonly accepted now that ROS are implicated in the regulation of aging
because of the increases in the production of ROS, but there is no consensus that this ROS-
induced damage is the underlying cause of aging [23,24]. The initial studies supporting the
theory that the deleterious effects of ROS come from the increasing of hypoxia during the
replication of human diploid fibroblasts with an increasing lifespan (theory of aging) [25].
However, recent theories suggest that an increase in ROS levels can activate cellular stress
pathways to reduce tissue degeneration, and that such an increase may be beneficial for
the maintenance of tissues [1,3,23].
As early as in 1970, researchers found that lipid peroxidation is increased during
exercise in humans and rats [23,26]. A few years later, researchers began to link ROS and
muscle function, finding that ROS are involved in normal muscle contraction [27,28]. Reid
et al. [27] reported that, under basal conditions, low levels of ROS need to be present in
skeletal muscles for their contraction, but antioxidant-mediated depletion of ROS prevents
their contraction, concluding that ROS that are produced during exercise have a physio-
logical role, signaling a modulated response of muscles to exercise [26,28,29]. In working
muscles, the generation of ROS as part of a beneficial physiological response is mainly
performed in the mitochondria, sarcolemma, and microcirculation [4]. The addition of
antioxidants, such as vitamin C and E, appear to blunt exercise-induced mitochondrial
biogenesis, as seen in Figure 1 [30,31]. Other reports suggest that the intake of vitamin
C supplements decreases oxidative stress and might increase exercise performance only
in those subjects with a low initial concentration of vitamin C [32]. It is believed that
the adaptations of muscles depend on the strength and endurance required for exercise,
and that these potential positive effects may not only be linked to the exercised muscles,
reducing fatigability and improving recovery, but also alleviating common cold symptoms
and exercise-induced bronchoconstriction, problems commonly associated with the upper
respiratory system [33].
ROS also have physiological effects in excitation–contraction protein processes within
cardiac muscles [34,35]. Several researchers found that ROS permit the regulation of Ca2+
signaling sensitivity through redox modifications, facilitating faster Ca2+ release during
cardiac activity [36]. ROS have also a role in encoded cell death and cancer, because of their
involvement in cell death processes. However, ROS overproduction may also be involved
in the defense of the host organism, by attacking the DNA of cancer cells [23].
Changes in oxygen concentration (oxygen homeostasis) are controlled via both res-
piratory ventilation and red blood cells [23]. Increasing evidence suggests that changes
in [O2] may be perceived independently by different ROS-producing proteins, including
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cytochrome b. Some literature reports indicate that ROS are involved in the control of red
blood cell mass and ventilation so that during an ischemia event, ROS limit erythropoietin
protein production, preventing both hypertension and the augmentation of blood viscosity.
ROS are also involved in the amplification of immune responses, which are redox-regulated
processes regulated through the activation of T lymphocytes or by a shift in the intracellular
glutathione redox state. Recent research has focused on the later stages of the immune
response in disease, suggesting that a moderate increase in the ROS levels of the immune
system might enhance normal immune function [23].
1.3. Antioxidants and Their Modes of Action
A conceptually important strategy to slow down the harmful effects of ROS is stimu-
lated by the endogenous security processes developed by biological systems to maintain
the redox homeostasis, so that they can protect themselves against induced cell damage.
This approach involves the use of chemicals that scavenge ROS, blocking their production,
chelating pro-oxidant transition metals, inhibiting enzymes associated with the over-
production of ROS, and recovering the antioxidant defenses by addition of exogenous
antioxidants [8,37]. Typical endogenous antioxidants that are involved in some of their
reactions are displayed in Table 4. Antioxidants (either endogenous or exogenous) are
effective as free radical scavengers because they are capable of donating H-atoms to coun-
teract the adverse effects of ROS [38] and they work at distinctive levels, keeping the
formation of reactive species to a minimum, and scavenging ROS by using non-catalytic
and catalytic molecules, e.g., alpha-tocopherol and ascorbic; this can also be achieved by
repairing damaged molecules, for example, regenerating antioxidants or lipid radicals to
their original species [38–40].
Table 4. Major enzymatic ROS scavengers in the antioxidant mechanisms. RX = redoxin, DHA = dehydroascorbate,
AsA = ascorbate, MDHA = monodehydroascorbate. Adapted from ref. [8].
Scavenger Acronym Catalyzed Reaction
Superoxide dismutase SOD M
(n+1)++SOD + O−2 → M
n++SOD + O2
Mn++SOD + O−2 +2H
+ → M(n+1)++SOD + H2O2
Catalase CAT 2H2O2 → O2+2H2O
Ascorbate peroxidase APX H2O2+AsA→ DHA + 2H2O
Monodehydroascorbate reductase MDHAR MDHA + NAD(P)H→ AsA + NAD(P)+
Glutatione peroxidase GPx 2GSH + H2O→ GSSG + 2H2O
2GSH + ROOH→ GSSG + ROH + H2O
Glutatione transferase GST RX + GSH→ HX + R− S−GSH
Polyphenolic antioxidants can be divided in two broad groups according to their
mode of action against ROS. Primary, chain-breaking antioxidants reduce or delay the
production of ROS, usually by trapping the generated free radicals. The secondary or
preventive antioxidants prevent the attack of ROS on a substrate. Primary (chain-breaking)
antioxidants inactivate free radicals through three main mechanisms that can operate
simultaneously, depending on the particular environmental conditions: (1) transferring H-
atoms to peroxyl radicals (the hydrogen atom transfer, HAT, mechanism); (2) the sequential
electron transfer-proton transfer (SETPT mechanism); and (3) the sequential proton loss-
electron transfer (SPLET) mechanism [38,39,41]. Some kinetic and mechanistic details can
be found elsewhere [8].
The HAT mechanism involves the hemolytic cleavage of the O-H bond, converting
them into harmless hydroperoxides and the oxidized antioxidant radical ArO•, which
is less reactive than ROS. The so formed ArO• radicals are not capable of triggering the
formation of fresh radicals, interfering in the free radical propagation pathways, as seen in
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Scheme 1, but can accept electrons from other radicals to form stable, non-radical products
(SETPT, SPLET mechanisms, Schemes 1 and 2) [41–43].
Scheme 1. Hydrogen atom transfer (HAT) and single-proton-loss electron-transfer (SPLET) reaction mechanisms between
antioxidants and peroxyl radicals. ArO-H: antioxidant, LOO•: peroxyl radical, S: solvent.
Scheme 2. Key reactions of lipid radicals (R•, RO• or ROO•) with antioxidants (ArOH) and antioxi-
dant radicals (ArO•).
The so-called preventive, or secondary, antioxidants retard oxidation through forming
thermodynamically stable complexes with pro-oxidative metal ions (ethylenediaminete-
traacetic acid (EDTA), citric and phosphoric acids), enzymes, and other promoters [44,45].
Synergistic or antagonistic effects may be observed when two or more antioxidants (AOs)
are present at a time, so that their scavenging reactivity is much higher or lower than that of
when used alone [44,45]. For example, the couple α-tocopherol/ascorbic acid is synergistic
in the inhibition of the lipid oxidation reaction, because tocopherols (primary antioxidants)
are replenished from their radicals by ascorbic acid, which is capable of donating hydrogen
atoms, inhibiting its depletion [46,47]. Other species that may recover antioxidants include
low-molecular-weight thiols and thioethers (methionine, glutathione, acetylcysteine, etc.).
1.4. Ongoing Development of Antioxidants
Addition of antioxidants may also have some effects of health. A large number of
reports have been published on the protective and therapeutic benefits of antioxidants in
cellular and animal models of cardiovascular, neurodegenerative, inflammatory diseases,
and cancer [48]. Consequently, antioxidant supplements have been considered, often with
little or no clinical control or evidence, either as nutraceuticals or antioxidant vitamins [4].
Many in vivo animal studies have failed to show their benefit in the clinic, in spite of
the beneficial effects shown by antioxidants [4]. However, a large number of epidemio-
logical studies have unequivocally associated the consumption of antioxidants (polyphe-
nols) with a decrease in the risk of development of diseases, including atherosclerosis,
cancer, and neurodegenerative processes [49]. Thus, current antioxidant therapies have
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focused on polyphenolic compounds, which donate H-atoms to radical species to minimize
radical concentrations.
One potential important problem in interpreting the cytoprotective effects of antiox-
idants relies on the chosen assays to monitor their action and on the systems where the
effects of ROS are monitored. Standard cell-free, cell culture, and isolated organs model
systems may bias results if experimental conditions do not reproduce those present in
real systems. For example, the exposure of cells to high concentrations of antioxidants is
certainly non-physiological, even though they may be reached in some subcellular com-
partments or in intercellular spaces [4,46]. Numerous in vitro assays have evaluated the
antioxidant activity of biological samples, but establishing comparisons between them is
difficult because of the different chemical assays involved (see Section 3.2).
Currently, the distribution of antioxidants is recognized as a crucial issue regarding
their efficiency at inhibiting the oxidation of target biomolecules in multiphasic systems.
Current research links the quantitative distribution of antioxidants in complex multiphasic
systems with the selection or design of antioxidants that preferentially distribute at the
bio-interfaces [18,47,50].
2. Antibacterial Activity of Polyphenolic Antioxidants: Interactions with
Cell Membranes
In addition to their beneficial effects on human health, phenolic compounds also play
a significant role in defense mechanisms against viruses, bacteria, fungi and herbivores,
making them behave as natural preservatives in agriculture and in the meat industry.
Phenolic antioxidants are chemical compounds, bearing at least an aromatic ring with one
or more attached hydroxyl groups, and several thousands of naturally occurring species,
from simple phenolic acids to highly polymerized compounds, have been described [51,52].
The major groups of phenols that show antimicrobial activity include phenolic acids,
coumarins, quinones, flavonoids, and tannins, as seen in Scheme 3, and variations in their
architecture and spatial configuration results in differential antimicrobial action.
Scheme 3. Chemical structures of some common antioxidants with antibacterial and anticarcinogenic
activity. Adapted from ref. [8].
The mechanism underlying the antibacterial activity of polyphenols is still a matter of
debate. Some researchers have argued that the antibacterial ability of polyphenols is related
to their ability to chelate metals, especially iron, which is vital for the survival of almost all
bacteria; however, others think that the inhibitory action comes from the interaction of the
Biomedicines 2021, 9, 1909 8 of 38
hydroxyl (-OH) group in phenolics with the cellular membranes of bacteria, disrupting
their membrane structures and causing the leakage of important cellular components,
as seen in Scheme 4. The strength of the interaction not only depends on the number
and position of the -OH groups in the aromatic ring, but also depends on the nature and
complexity of the bacterial cell wall [53]. For instance, Gram-positive bacteria are less
resistant to plant extracts, oils, and their constituents than Gram-negative bacteria, because
the cell wall of Gram-negative bacteria is more complex [54]. Hydrophobic molecules
penetrate easily through the cell walls of Gram-positive bacteria, acting on both the cell
wall and in the cytoplasm [55], meanwhile only small, hydrophilic solutes can penetrate
the cell walls of Gram-negative bacteria, and this is one of the reasons why Gram-negative
bacteria are more resistant to polyphenolic action [56].
Scheme 4. Changes in the number and position of substituents in the aromatic ring (thymol-carvacrol, eugenol-isoeugenol,
caffeic acid—4-hydroxycinnamic acid) lead to changes in antibacterial effectiveness.
It is believed that polyphenols interact with the outer bacterial membrane through non-
specific forces, including hydrogen bonding and hydrophobic and lipophilic effects, [57]
leading to physical interactions with the phospholipids of the lipid bilayer and with the
membrane proteins [58]. For example, in bacteria (both Gram-positive and Gram-negative)
the physical interactions of polyphenols with membrane proteins disrupts the lipid bilayer
and perturbing membrane fluidity, causing increases in membrane permeability and
modifying ion transport processes [57].
The number and position of -OH groups in the aromatic ring and the length of the
saturated/unsaturated side chain are also factors influencing antimicrobial activity [59].
Gallic and ferulic acids impact irreversibly the membrane properties of E. coli, S. aureus,
P. aeruginosa, and L. monocytogenes [60]. It was postulated that gallic and ferulic acids
produce a decrease in the (negative) surface charge of bacterial cytoplasmic membranes,
modifying their hydrophobicity and leading to the formation of pores that allow the
leakage of intracellular constituents [61]. Attachment of alkyl or alkenyl groups to the
aromatic ring also affects the antimicrobial activity of phenolic compounds. For instance,
benzaldehydes with two or more adjacent -OH groups have been reported to be more active
than aldehydes, as benzaldehydes are thought to act primarily on the external surface of
the cells, combining with sulphydryl groups of proteins [62,63].
3. Bioactivity of Antioxidants
3.1. Bioavailavility of Phenolic Antioxidants
The bioavailability of phenolic antioxidants in humans is still not well understood,
because before becoming bioavailable, antioxidants must be released from complex foods
matrices and suffer several modifications in the gastrointestinal (GI) lumen. Therefore, any
potential health effect obtained by the consumption of antioxidants is dependent on their
effective bioaccessibility and bioavailability.
The bioavailabilities of phenolic antioxidants are quite different from each other, even
within each class of phenols, as seen in Scheme 3, and frequently the most abundant
antioxidants in foods are not necessarily those with the best bioavailability or bioactivity
in humans. The physicochemical characteristics of antioxidants, such as their structure,
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molecular weight, and glycosylation will impact their solubility and are critical factors in
their bioavailability. Small molecules such as hydroxytyrosol, flavonoids, or phenolic acids
are usually easily absorbed in a dose-dependent manner [64] and are detected in plasma as
parental compounds or as their metabolites, within 5 h after consumption [60,65,66]. In
contrast, polymeric polyphenols, such as proanthocyanidins, are poorly absorbed [60,67].
Moreover, phenolic rings with more hydroxyl and less methoxy groups show, in general, a
lower bioavailability [68].
After ingestion, antioxidants must pass from the gut lumen into the circulatory system
in order to be absorbed. Due to the special acid environment of the stomach, the more
liposoluble phenols can cross the gastric mucosa, mainly by passive diffusion [69,70],
but due to relatively low time of residence, the absorption in the stomach is considered
relatively low and untimely; their absorption will happen to a greater extent in the small
intestine. In nature, phenols are usually in the form of glycosides, which substantially
decreases their liposolubility, and prevents their transport through membranes. Therefore,
usually the attached sugar must be hydrolyzed before absorption [70]. This hydrolysis may
take place at the brush border of the enterocyte (Figure 2) and is usually catalyzed by lactase
phlorizin hydrolase (LPH), with the release of the much more lipophilic aglycone [71]. The
aglycone is then able to enter the enterocyte by passive diffusion. Alternatively, glycosides
can be transported into the enterocyte by active transport through a sodium-dependent
glucose transporter (SGLT1) [72] And then be hydrolyzed by cytosolic β-glucosidases
(CBG), as seen in Figure 2, inside the cell.
Figure 2. Illustration of the complex in vivo polyphenol metabolism. In the intestinal lumen, phenolic
glucosides are hydrolyzed by lactase phloridzin hydrolase (LPH) in the brush border of the enterocyte.
The phenolic aglycone is able now to enter the enterocyte, and is conjugated by uridine diphosphate
glucuronosyl transferase (UGT) or sulfotransferase (SULT) enzymes. The conjugated metabolites
can then be sent back to the intestinal lumen or sent into the bloodstream through several ATP-
binding cassette transporters (ABC). Conjugated metabolites can be taken by hepatocytes through
a series of uptake transporters (OAT transporters) and then send back to the circulatory system
or they can be deconjugated in the cell by enzymes such as β-glucuronidase (β-GlA) and suffer
further metabolism before being sent to the bloodstream. BG, β-glucosidase; CBG, cytosolic BG;
SCLT1, sodium-dependent glucose transporter; OAT, organic anion transporter; OATP, organic anion
transporting peptide.
Dozens of new compounds can arise from the metabolism of each phenolic com-
pound, which makes the fate of each compound in the body difficult to follow [70]. These
metabolic processes convert the phenolic antioxidants, in most cases, to completely distinct
molecules, whereas the parental phenol cannot be detected [70]. Once inside the enterocyte,
xenobiotics may first undergo a functionalization reaction (phase I metabolism) of oxida-
tion, reduction, or hydrolysis, which introduces or exposes a functional group, such as a
hydroxyl group, suitable for conjugation (phase II metabolism) [70,71]. In the case of phe-
nolic antioxidants, the phenolic ring gives to these compounds some metabolic pathways
that are shared by all classes of phenolic compounds [65,70]. In the enterocyte, usually
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the aromatic structures are kept untouched, but the free hydroxyl groups at the aromatic
ring of phenols are efficiently conjugated with the production of glucuronides, sulfates,
and/or methylated metabolites through the action of uridine-5-diphosphate glucuronosyl-
transferases (UDG), sulfotransferases (SULT), and catechol-O-methyltransferases (COMT)
(Scheme 5) [69,73]. The catecholic antioxidants’ conjugation usually occurs preferentially
at the meta position [70,74]. Nevertheless, conjugation with glucuronic acid or a sulfate
group may also occur at the para position, usually after conjugation at the meta position
with a methyl group. In contrast, derivatives of gallic acid may conjugate preferentially
at the para position [73].
Scheme 5. Main conjugation reactions of phenolic hydroxyl groups: glucuronidation, sulfonation,
and/or methylation through the action of uridine-5-diphosphate glucuronosyltransferases (UDG),
sulfotransferases (SULT), and catechol-O-methyltransferases (COMT).
Nevertheless, further phase I metabolic reactions may still take place inside the en-
terocyte by the action of several enzymes, such as dehydrogenases, in the non-phenolic
moiety of antioxidants.
Once conjugated by SULTs and UGT, the ability of compounds to cross membranes
deeply decreases, due to the attached anionic hydrophilic moiety and specific transporters
are now required [75]. Conjugated metabolites can be sent back to the intestinal lumen
through specific efflux ATP-binding cassette transporters (ABC transporters) or sent to the
bloodstream by other ABC transporters and reach the liver via the hepatic portal vein. Here,
several organic anion transporters (OAT) families, namely the organic anion transporting
peptide (OATP) family and the multidrug resistance-associated protein (MRP) family (ABC
transporters), will allow the conjugated compounds to enter the hepatocyte. However,
these transporters are quite specific for the class of phenols, to the type of conjugated group,
and conjugated position in the molecule [76].
Once in the hepatocyte, some conjugates may be sent back to the bloodstream and
distributed to other organs tissues or up taken into the kidney proximal tubular cells by
transporters and excreted into the urine. In contrast, other conjugates can be deconjugated
in the cell by enzymes such as β-glucuronidase (β-GlA) or sulphatases. Intracellular
deconjugation is enhanced under inflammatory conditions, and seems to have an important
role in the bioactivity of many conjugated metabolites. For example, there is growing
evidence that intracellular desulfation plays an important role in the availability of active
steroid hormones near the target sites [77]. In fact, the role of phase II conjugates as
temporary deposits in tissues has recently attrated some attention [78,79].
In the liver there are two main metabolic reactions that are associated with the
metabolism of xenobiotic compounds: conjugation, catalyzed by the enzymes UGA, SULT,
COMT, as seen in Scheme 5, and also by glutathione-S-transferases and oxidation, reduc-
tion and hydrolysis reactions, mainly catalyzed by the cytochrome P450 enzyme system, a
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superfamily of membrane-bound isoenzymes. Nevertheless, a number of non-cytochrome
P450-dependent reactions also occur in the liver. Moreover, although the majority of
metabolic reactions occur in the liver, cytochrome P450 isozymes are presented in other
tissues, including the gastrointestinal tract itself, the lungs, kidney, and skin. Therefore,
each phenolic antioxidant may produce in the body a huge number of compounds, dis-
tributed in different concentrations over the different tissues and organs, depending on
their capacity of being transported, and are then metabolized and eliminated by cells, with
each of these metabolites being bioactive, weakly bioactive, reactive with endogenous
macromolecules, or non-active at all.
It is estimated that only 10–15% of polyphenols are absorbed in the small intestine [76].
Therefore, most reach the large intestine and are subjected to the action of the intestinal
microbiota, producing a wide number of metabolite compounds. Therefore, most of the
observed bioactivity of antioxidants results from the metabolism performed by the gut
microbiota, rather than the original dietary antioxidants [70]. A number of microbiota
enzymes are able to hydrolyze glycosides, to catalyze ring fissions leading to the produc-
tion of smaller phenolic compounds, and to oxidize or reduce the non-phenolic moieties
of antioxidants [80,81]. These more lipophilic metabolites can then be absorbed, to be
subjected to phase II metabolism and this may be responsible for a large extent of the
bioactivity of antioxidants (Figure 2). Ring fusions are of particular importance in the
case of flavonoids, as this class of phenolic antioxidants will produce small phenolic acids,
sometimes with a higher bioactivity than the parental flavonoid. The microbiota is able to
catabolize flavonoids into C6−C3 phenolic catabolites that, in turn, can be converted by
two α-oxidations or via β-oxidation into C6–C1 phenolic compounds. C6−C2 phenolic
catabolites usually arise independently, possibly by α-oxidation [82–86]. Many of these
transformations can be catalyzed by both the microbiota’s and/or mammalian enzymes.
Increasing evidence suggests that microbiota phenolic catabolism is responsible for much
of the flavonoids bioactivity [87,88].
The importance of the microbiota to the bioactivity of antioxidants has gained huge
interest in the last decade and it has shown to be one of the most important causes of
interindividual variations that are observed in antioxidant bioavailability. Substantial in-
terindividual variation has been observed in the excretion recovery of flavonoids and olive
oil secoiridoids, ranging from 2 to almost 60% of the ingested phenolic compounds [89].
In fact, in many studies gender, body mass index, or even age and drug intake were not
the primary cause of interindividual variations, but they may be related with the different
intestinal microbiota of individuals [89,90]. Moreover, the presence of antioxidants seems
to modulate the existing microbiota, suggesting their application in foods as probiotics [91].
3.2. Bioactivity of Phenolic Antioxidant Metabolites
As mentioned in Section 1.1, an imbalance between the generation of reactive oxy-
gen and nitrogen species, namely hydroxyl radicals, superoxide anion radicals, hydrogen
peroxide and nitric oxide, and antioxidant protection results in a disrupted condition
called oxidative stress, which causes disturbances such as lipid oxidation, DNA mutation,
and protein cross linking, which ultimately leads to cell malfunction, tissue damage, and
necrosis. At a later stage, this will trigger oxidative stress associated with degenerative
complications such as cancer, diabetes, as well as cardiovascular (CVD), liver and neu-
rodegenerative (NDD) diseases. Hypertension, dyslipidemia, hyperglycemia, and obesity
occur very often in people suffering from CVD, NDD, and diabetes, and these chronic
conditions are usually intimately related with inflammatory conditions. Hence, natural
antioxidant compounds with a free-radical scavenging capacity should be considered as
powerful candidates for the prevention and treatment of these diseases.
In general, phenolic antioxidants and their metabolites are present in plasma and
tissues at concentrations more than 50-fold lower than the pool of endogenous antioxidants
and, therefore, their contribution to the overall body oxidative status is likely to be quite low
when compared to other endogenous oxidizable substrates, including vitamin E, vitamin
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C, urate, tiols, bilirubin, proteins, enzymatic systems, and unsaturated fatty acids [76].
Moreover, phenol-conjugated metabolites have frequently shown a much lower radical
scavenging capacity than the parental compounds and, unless some intracellular de-
conjugation happens, they are quite inactive as antioxidants [92,93]. Nevertheless, it is
known that a relatively low plasma concentration of some drugs that are given at regular
low doses (for example aspirin) can confer health benefits to patients [94]. Therefore, it is
possible that the regular low lifetime intake of dietary phenolic antioxidants results in an
overall antioxidant protective effect. This phenomenon has been observed in clinical trials,
showing that the short-term consumption of olive oil (50 mL/day) rich in phenols could
change several oxidative stress markers [95,96], although the concentration of these phenols
was lower than those required to show in vitro biological activity. In general, antioxidant
actions on human physiology are moderate and, as food components, they should not
be regarded as drugs. Usually, the possibility of accumulation in particular tissues and
their link to cellular proteins and lipoproteins is not known for most phenolic antioxidants,
and probably underestimated. In fact, food and its components are ingested throughout a
lifetime, during which even modest antioxidant effects may become noteworthy. Moreover,
due to the strong possibility of additive or synergetic effects between phenols, it is difficult
to predict the real contribution of these compounds to human health. Actually, it is
important that antioxidants are consumed at the normal concentration found in foods and
as part of the natural protective food matrix. Phenolic compounds may act as pro-oxidants
when consumed in high doses as supplements or in the presence of transition metal ions
inside the human intestinal tract, where they may induce oxidative damage [97,98].
There are several methods for evaluating the in vitro antioxidant activity of phenolic
compounds, including the 2,2-diphenyl-1-picrylhydrazyl (DPPH) essay, the ferric reducing
antioxidant power (FRAP), the oxygen radical absorbance capacity (ORAC), or even cell-
based antioxidant assays [18]. However, the radical scavenging activity of antioxidants
may vary against different oxidants. For instance, some phenols may exhibit a high
radical scavenging activity against hydroxyl radicals, but a low capacity against superoxide
anions [99]. Furthermore, monophenols do not show radical scavenging activity with
several radicals used to evaluate in vitro radical scavenging activity, such as the DPPH• [92].
However, in vivo, highly reactive radicals, such as the hydroxyl radical, are formed and can
be trapped by monophenols in a similar fashion to the amino acid tyrosine that is present in
all membrane proteins. Although the assessment of antioxidant activity using these in vitro
tests is more or less quick, it has been clear that the bioactivity of phenolic antioxidants
in vivo cannot be related to their in vitro antioxidant capacity without considering their
bioaccessibility and bioavailability. Thus, in 2012, the USDA’s Nutrient Data Laboratory
removed the ORAC Database for Selected Foods. Nevertheless, although the mechanism
of action of phenolic antioxidants is still unrevealed, the underlying idea that phenolic
antioxidants protect humans against oxidative stress remains valid [76], as diets which
are deficient in natural phenolic antioxidants confer a strong risk factor for developing
many chronic diseases [100]. Moreover, several interventional studies have linked the
consumption of phenolic antioxidants with a lower prevalence of the most common chronic
diseases such as diabetes type II, and cancer, as well as cardiovascular and neurovascular
diseases, Figure 3.
Polyphenols have multiple therapeutic targets and bioactivities, as seen in Figure 3.
Inside the gut they can reduce caloric intake by inhibiting digestive enzymes [101–103],
such as β-amylase, β-glucosidase, and lipase, which prevents the increase in blood triacyl-
glycerols and glucose concentration, and modulates the intestinal microbiota by favoring
beneficial bacteria.
After being absorbed into the bloodstream, some metabolites are still able to scavenge
reactive oxygen [92,93]. However, phenolic antioxidants led to the reduction of oxidative
stress not only by scavenging ROS, but mostly by genetic modulation, as seen in Figure 3.
In fact, phenolic antioxidants are capable of reducing the expression of ROS-generating en-
zymes/pathways, and increasing the expression and activity of antioxidant enzymes [104].
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In addition, phenols also modulate the expression and activity of enzymes involved in
lipid metabolism, such as the pancreatic lipase and carnitine palmitoyltransferase (CPT),
affecting the concentrations of cholesterol and triacylglycerides in the blood [105,106].
Phenolic antioxidants are also able to increase the expression, translocation, and activity of
glucose transporters and modulate the pathways of carbohydrate metabolism, lowering the
blood concentration of glucose [107]. Moreover, they are also able to reduce body weight
by decreasing the concentration of leptin and the expression of adipogenesis-activating
genes, and by increasing the amount of adiponectin and the expression of thermogenesis
genes [108], as seen in Figure 3. Other genetic modulatory activity has been attributed
to phenolic compounds, such as the up-regulation of the CB1 tumor suppressor gene in
human colon cancer cells [109].
Figure 3. The bioactivity of phenolic antioxidants and some of their main mechanisms of action. Cyclooxygenase (COX),
lipoxygenase (LOX), intracellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), vascular
cellular adhesion molecule-1 (VCAM-1), inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS);
tumor necrosis factor-α (TNF-α); extracellular signal regulated protein kinase (ERK); interleukin (IL), phosphoinositide
3-kinase (PI3K); transforming growth factor-β (TGF-β1).
Many other mechanisms of action have been addressed to antioxidant phenolic com-
pounds, one of them being their capacity to modulate the host immune cells’ response
through binding to cell receptors and the modification of intracellular signaling pathways,
as well as the induced expression of genes, as seen in Figure 3. Some have shown to be
able to elevate the concentration of immune cells, namely, dendritic cells, macrophages,
neutrophils, T helper 1 cells, natural killer (NK) cells, and B cells [110], which are beneficial
for infectious disease prevention. NK cells have a key role in the body’s defense against
cancer cells. On the other hand, some phenolic antioxidants have also shown the capacity
to inhibit the release of histamine from mast cells [111] and to increase regulatory T cells,
that have a key role in immunotolerance and prevent the development of immune diseases,
such as allergies, rheumatoid arthritis, type I diabetes, and Crohn’s disease [112].
The most important cells in inflammatory responses, critical for immune diseases, are
probably macrophages. These cells initiate inflammatory responses through the production
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of various pro-inflammatory mediators such as cytokines, prostaglandin E2, IL-6, and
tumor necrosis factor α (TNF-α), but they also produce those with chemotactic activity,
chemokines (Figure 3). Many phenolic antioxidants have shown, both in vitro and in vivo,
to suppress the expression, production, and secretion of inducible nitric oxide synthase
(iNOS), cyclooxygenase-2 (COX-2), TNF-α, and IL-1-β [113]. Moreover, the consumption
of selected phenols has shown in patients with a high risk of cardiovascular disease (CVD)
to reduce E-selectin, monocyte chemoattractant protein-1 (MCP-1), intracellular adhe-
sion molecule-1 (IDM-1), IL-16, CD40 antigen and ligand, and vascular cellular adhesion
molecule-1 (VCAM-1) [114].
One of the main anti-inflammatory, anti-thrombotic, and anti-hypertensive mecha-
nisms of action of many phenols is the inhibition of eicosanoid biosynthesis, including
PGE2, leukotriene B4 (LTB4), and thromboxane B2 (TXB2) [115]. COX-1 and 12-LOX
pathways produce arachidonic acid radical derivatives and, therefore, antioxidants may
inactivate the production of these mediators through a radical scavenging mechanism
based on their reaction with the tyrosyl radical in COX-1, and the reduction of iron (III) to
iron (II) in 12-LOX. Nevertheless, in spite of their lower radical scavenging capacity, the
anti-inflammatory activity of phenols through the modulation of COX-1 and 12-LOX path-
ways does not seem to depend on the number of OH groups, as some monophenols, such as
olocanthal, a tyrosol derivative from olive oil, demonstrate a strong anti-inflammatory ac-
tivity. The apparently contradictory observations in the variation of the anti-inflammatory
capacity of compounds with a different number of phenolic hydroxyl groups may be
related to differences in the interaction of compounds with the different active sites of
enzymes. Nevertheless, and whatever the mechanism, it seems clear that many phenolic
antioxidants are able to effectively modulate hemostasis, as well as endothelial and platelet
function, and inflammatory biomarkers [110].
The intensity of the bioactivity of phenols depends heavily on their structure. For
example, in order to show immunosuppressive activity, flavonoids need to hold a methoxyl
group at the C’4 position and a hydroxyl group at the C-5 position, as seen in Scheme 3.
This activity is usually increased by the presence of hydroxyl groups at both 3′-and 4′-
positions in the B-ring and is higher than the one observed for those with 3′-,4′- and
5′-OH groups but, as already mentioned, having more than a phenolic hydroxyl group is
not always needed. Glycosides usually have a weaker activity than their aglycones, but
their immunosuppressive activity also depends on the size, position, type, and number
of glycoside sugar moieties [110]. Nevertheless, the anti-inflammatory activity of phenols
through the modulation of COX-1 and 12-LOX pathways, as mentioned above, does not
seem to depend on the number of phenolic OH groups [116].
The conjugation of phenolic hydroxyl groups usually decreases their radical scaveng-
ing capacity [92,93] but, depending on the position of this conjugation, both sulfate and
glucuronide metabolites may present a much higher biological activity than the parental
compound. This is the case, for example, of sulfate conjugates of daidzein [117] and
glucuronides of urolithin A [118]. The presence of more hydroxyl groups, or sugar or
sulphate moieties in the molecule, will not only affect the radical scavenging capacity of
compounds but also other important properties for their antioxidant activity, namely their
metal chelating capacity.
Despite their bioavailability controversies and their complex mechanism of action,
oral phenolic antioxidant intake exhibits promising results as alternatives to drug interven-
tions in preventing many chronic diseases, such as CVD and NDD, in at-risk populations.
Dietary phenols, both in vitro and in vivo, have been demonstrated to display numer-
ous beneficial bioactivities, namely showing anti-atherosclerotic, anti-hypertensive, and
anti-cancer properties. Nevertheless, further studies are still needed for the complete
understanding of the bioavailability and bioactivity of phenolic antioxidants in vivo, and
to relate this bioactivity with their metabolites and the phenolic composition of foods.
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4. Reactivity of Polyphenols: Radical Scavenging, Chelating Properties and
Structure-Reactivity Relationships
4.1. Polyphenols as Free-Radical Scavengers
The effectiveness of phenolic compounds in inhibiting the production of ROS is related
to their reactivity against radicals and to their effective concentrations at the reaction site.
In this section, we will discuss the effects of phenolic architecture on their reactivity;
meanwhile the concentration effects will be discussed later in Section 6. All polyphenols
bear at least one -OH group attached to an aromatic ring, and mainly scavenge free radicals
by H-atom transfer from the -OH group(s) of polyphenolics to the free radical, as seen
in Scheme 1 (HAT mechanism), although other mechanisms (sequential proton-electron
transfer (SPLET), proton-coupled electron transfer (PCET), and single electron transfer
followed by proton transfer (SETPT)) may operate simultaneously, depending on the
particular experimental conditions employed, as seen in Schemes 1 and 2 [42,119].
4.2. Structure-Reactivity Relationships
Several literature reports suggest that the oxidation–reduction, Ep0, potential values
of polyphenols correlate with their antioxidant activity, so that a decrease in the redox
potential values leads to an increase in the radical scavenging ability [120–123]. Correlations
between Ep0 values and antioxidant activities have been proposed for some series of AOs,
but data need to be taken with caution, because Ep0 values are strongly affected by the
nature and position of substituents on the aromatic rings of the polyphenols, altering
strongly their antioxidant efficiencies [120,121]. Decreases in Ep0 values have been reported
for phenols that are methoxylated in the ortho-position of a phenolic hydroxyl group
(e.g., ferulic acid series), and concomitant increases in their antioxidant activity have been
observed. The introduction of a second methoxyl group in the other ortho position, with
respect to the phenolic hydroxyl group (e.g., sinapic acid series), further decreases the
Ep0 value (relative to that of ferulic acid), usually increasing even more their antioxidant
activity. Addition of a second hydroxyl group to the phenolic ring, both in the ortho
or in the para position, e.g., catecholics, leads to an increase of the radical scavenging
activity, which is not only due to the higher resonance stabilization of the phenoxyl radical
intermediate, but also because the produced initial semiquinoid radical can be further
oxidized to a quinone by the donation of a second hydrogen atom to another lipid radical
with subsequent ortho- and para-quinone formation, respectively. In fact, monophenols have
been described as oxidizing in a one-electron, one-proton irreversible step to a phenoxy
radical [32], but the oxidation mechanism of AOs bearing the catecholic moiety usually
involves a two-electron and two-proton reversible process [124]. Ortho-catechols are usually
better antioxidants than most para-catechols, due to the stabilization of the semiquinone
radical formed through strong internal hydrogen bonds [125].
An ethylenic side chain, connecting the aromatic ring to a carboxylic group, increases
the reducing properties of phenolic acids. Nevertheless, the redox potential obtained for
hydrocaffeic acid, where conjugation between the aromatic ring and the side alkyl chain is
not possible, has been found to be lower than the one for caffeic acid. This suggests that the
extension of the resonance over the alkyl side chain depresses the electronic density at the
aromatic hydroxyl groups, decreasing their ability to donate H-atoms. These observations
are in accordance with the bond dissociation enthalpy (BDE) and the ionization potential
(IP) values that have been calculated for caffeic and dihydrocaffeic acid, that were found
to be lower for the former. From the reactivity (kinetics) point of view [8], attachment
of electron-donating substituents in the benzene ring of phenols, particularly at the ortho
and/or para positions of the phenolic hydroxyl group, increases their radical scavenging
activity by lowering the phenolic O–H bond dissociation enthalpy, thus increasing the rates
of the reaction with peroxyl radicals.
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4.3. Polyphenols as Chelators of Pro-Oxidant Metals
Transition metals play an important role as catalysts in the oxidation of biomolecules,
when present in the appropriate oxidation state [8]. Most of the hydroxyl radical production
in biological systems is a consequence of two main chemical reactions [126,127]. In the first
one, the oxidation of biomolecules is initiated by the hydroxyl radical (HO•), generated
in the reaction between the redox-active transition metal and hydrogen peroxide, by
removing an electron from the participating metal ion (Fenton-type reactions) [126], as
seen in Scheme 6. The original metal ions may be regenerated in a subsequent reaction
(Mn+ + O2•− →M((n−1)+ + O2). This overall set of reactions constitutes the Haber–Weiss
process, shown in Scheme 6, which is a combination of Fenton-type reactions and the
reduction of Mn+ by O2•−, yielding M(n−1)+ and oxygen. Thus, control of metal levels in
cells (especially Fe) is of particular importance, as increased concentrations may lead to
undesirable reactions with oxygen to overproduce ROS [128–131].
Scheme 6. Examples of redox reactions involving ROS, metals (Mn+) and β-amyloid protein
(Aβ) [132,133].
Antioxidants bearing only one -OH group in their structure (e.g., vanillic, syringic
and ferulic acids) do not chelate metals, but those bearing the catechol or galloyl moieties,
as seen in Scheme 7, are able to form complexes with typical stoichiometry of 3:1, 2:1 and
1:1 (antioxidant: metal) [134]. Flavonoids, as seen in Scheme 3, containing hydroxyl groups
at the 3, 5, 3′, and 4′ positions, and carbonyl at the four position, possess three sites where
metal complexes can form; the stoichiometry and stability depend on the number and type
of the functional groups and pH [135].
Scheme 7. Some common metal chelators.
5. Challenges on the Application of Antioxidants: Encapsulation and Delivery
There is a great interest in polyphenols as strong antioxidants, and their importance in
food, pharmaceutical and cosmetic industries is evident. Although the antibacterial, antivi-
ral, and anti-inflammatory potential of these antioxidants has been shown, the preparations
containing polyphenols have limited in vivo activity. One of the most important factors
that affect the delivery of polyphenols is their poor in vitro and in vivo stability [136,137].
Factors such as the temperature, light, and oxygen make them susceptible to degradation
during storage and processing. Upon oral administration, the harsh gastrointestinal con-
ditions, with an acidic pH and enzymes, lead to rapid degradation. The gastrointestinal
barriers and poor solubility are also other factors responsible for low bioavailability. An-
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other problem is the unpleasant taste of the polyphenols, which has to be masked before
oral administration [138]. Therefore, in order to strengthen the potential usage of antioxi-
dants, it is essential to maintain their structural integrity via special formulation strategies.
Encapsulation, lyophilization, and emulsification are among these approaches [139].
5.1. Encapsulation Strategies for Antioxidants
Encapsulation has been a developing technology since the early 1930 [140]. It is
the process of loading active molecules within carrier systems or shells, thus improving
their physicochemical and biological properties [141]. The carrier material that protects
the encapsulated material is generally made of polymers or lipids [18,50,142]. Natural
(agar, albumin, gelatin, chitosan, starch, pectine, collagen, etc.) or synthetic polymers
(polyethylene glycol, polyesters, poly vinyl pyrrolidone, poly vinyl alcohol, etc.) are
commonly used. The major advantages these systems are as follows:
- Provide improved in vitro and in vivo stability of the encapsulated cargo,
- Modify the drug release profile and provide controlled release,
- Can be incorporated into different dosage forms including capsules, tablets, suspen-
sions, gels, creams, etc.
- Site specific drug delivery,
- Reduce the inter- or intra- subject variability of the pharmacokinetic parameters,
- Good biocompatibility,
- Undesired side effects of the drugs can be reduced, and lower drug doses can be used
which will improve patient compliance.
In order to provide the therapeutic use of polyphenols as new pharmaceutical prod-
ucts, their encapsulation is widely studied. The comprehensive advantages of encap-
sulating antioxidants include improved stability, controlled compound release, masked
unpleasant odor or flavor, protection from the evaporation, improved solubility, permeabil-
ity, and overall bioavailability. Besides that, encapsulation of polyphenols was shown to
improve their potential cosmetic applications for skin pigmentation disorders, skin aging,
and skin solar protection [143].
5.2. Antioxidant Loaded Drug Carrier Systems
In order to exert their intended effects, antioxidants must pass through many obstacles
present in biological systems. Their encapsulation into micro- and nanocarriers has opened
new horizons for improving their effects. Based on the production methods and materials,
micro- or nanoparticles are obtained. The size of microparticles and nanoparticles ranges
between 1–1000 µm and 1–1000 nm, respectively. The well-known structures are matrix
and reservoir systems, and they can carry solid, liquid and gaseous materials [144]. These
systems are characterized in terms of particle size and distribution, morphology, surface
charge, encapsulation efficiency, production yield, in vitro drug release, stability, and tox-
icity [145]. The microcarriers usually have a better loading capacity when compared to
nanocarriers, and the scale-up is easier [145]. For the microencapsulation of polyphenols,
a diverse array of microparticular systems have been prepared by different manufactur-
ing methods, including spray drying, lyophilization, extrusion, inclusion complexation,
coacervation, and fluidized bed coating [146]. However, in recent years, nanosized drug
delivery has received considerable interest, due to their numerous advantages. Due to
their small size at nano range, and their increased surface area, nanocarriers have unique
properties. They can circulate in the blood for a prolonged time, carry one or more active
substances, target specific tissues, and improve the solubility and therapeutic efficacy of
the encapsulated drug. Thus, besides reducing the toxicity of the active substance, its
biocompatibility and bioavailability can also be increased. There are numerous studies em-
phasizing the success of polyphenol-encapsulated drug delivery systems and some of these
are summarized in Table 5. Each of the listed carrier systems has their own advantages and
disadvantages. The selection of the most suitable system for a specific antioxidant highly
depends on its biological (absorption, distribution, metabolism, elimination, biological
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half-life, side effects, therapeutic index, etc.) and physicochemical (solubility, partition
coefficient, pKa value, molecular weight, solubility, etc.) properties.
Table 5. Examples of Micro-/Nano-Particulate Delivery System Containing Polyphenols.
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[160]
5.3. Importance of the Biointerface on Particulate Drug Delivery
Blood and plasma interactions, rapid clearance, presence of biological membranes,
such as the blood brain barrier or gastrointestinal barrier, biological hydrogels (such as
mucus), and the immune system reduce the effectiveness of drug carriers. The success of
these systems highly depends on their bio interface, which can be tailored via physicochem-
ical engineering. The morphological (particle size, shape, and rigidity) and topographical
properties, surface chemistry, and the presence of responsive materials are several factors
that influence the drug carrier interface [161].
Upon the absorption of plasma proteins onto nanocarriers, the protein corona structure
is formed, and this highly affects their interactions with immune cells [162]. Surface
morphology and chemistry are effective parameters on the protein corona formation.
Particularly, the particle size of the carrier has been found to influence the thickness of the
protein corona and the penetration of the encapsulated cargo through size-limited biological
barriers [163]. Both the formulation (type and concentration of the chemical components,
addition of ligands etc.) and process parameters (sonication time and rate, temperature,
homogenization cycles and power etc.) can be changed to adjust the particle size.
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It is important to consider the shape and rigidity of the particles as well when deter-
mining the in vivo efficacy of the carriers. Although the majority of the delivery systems
are spherical, some other carrier shapes, such as disks, rods, and worms, are also reported.
For instance, the phagocytic uptake of elongated particles was lower than that of spherical
particles. and this was attributed to the alignment of the particles during the particle–
cell interaction [164]. Non-spherical particles showed a higher circulation time than the
spherical particles. The shape of the nanocarriers impacts the margination and adhesion
process, and can alter the accumulation site of the carrier. This phenomenon can be used
for site-specific drug delivery. Additionally, as the surface areas of non-spherical shapes are
larger, surface modifications via ligands for targeted drug delivery is more feasible [165].
The surface chemistry of the particles is in direct contact with the biological medium.
In order to increase the bio interface between biological membranes and the nano/micro
particles, or to provide targeted drug delivery, the particle surface can be modified in terms
of its charge, hydrophilicity, and ligand attachment. Besides, the modification of particles
by dynamic materials that respond to biological stimuli, such as pH, redox, enzymes, and
temperature improve their in vivo performance.
Therefore, the bio interface between the drug carrier and the biological system has an
important role in the in vivo fate of the administered compound, and these carriers can be
engineered accordingly at the formulation stage.
6. Some Common Delivery Systems
6.1. Cyclodextrins
Cyclodextrins, CDs, are a family of oligosaccharides, composed of six (α-CD), seven
(β-CD), or eight (δ-CD) glucose residues, linked by a α-(1–4) glycosidic bond. In spite of
α-,β-,δ-CDs being the most common CDs, a variety of CD derivatives have been developed
with the objective of enhancing the physicochemical properties of natural CDs. For example,
to increase the water solubility of β-CD (1.85% w/v, T = 25 ◦C [19], chemically modified
β-CDs (hydroxypropyl (HP), randomly methylated (RM) β-CDs with aqueous solubilities >
600% w/v and >500, respectively, T = 25 ◦C [166] have been synthesized and widely used in
the pharmaceutical and food industries. Due to their physical characteristics and chemical
stability, (CDs) are widely employed as carrier systems to deliver the needed amount of
bio-active compound to the targeted site for the necessary period of time [166–168].
CDs are commonly described as a truncated cone or torus, with a hydrophobic inner
cavity and a hydrophilic external surface, as seen in Figure 4A. The nonbonding electron
pairs of the glycosidic oxygen bridges are directed toward the zone inside, leading to a
high electron density. In contrast, the primary and the secondary hydroxyl groups are
distributed on the narrow (primary face) and wider (secondary face) rims, respectively, of
the truncated cone shape.
This structure enables them to form host–guest complexes with a variety of polar and
apolar antioxidants (“guest“ or substrate, AO), as seen in Figure 4B, changing their physical-
chemical properties (e.g., solubility, antioxidant efficiency). CD–antioxidant (AO − CD)
inclusion complex formation, characterized by an inclusion constant KAO (Equation (1)
for a 1:1 complex), is a dynamic equilibrium process where AO − CD is formed by the













The main forces involved between the substrate (AO) and CD are weak, non-ionic
interactions (hydrophobic, electrostatic, van der Waals forces, hydrogen bonding, charge
transfer interactions etc.) but never by complete covalent bonds. These weak interactions
are responsible for keeping the guest substrate and host together, with a complete or partial
adjustment of the cavity [168,170]. Commonly, the stoichiometry of the inclusion complex
AO− CD is 1:1, representing the interaction of a single AO molecule with the CD; however,
other stoichiometries (1:2, 2:1, 2:2) can also be found [168]. Parameters such as the relative
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sizes and shapes of the free molecules can affect to the stoichiometry of the inclusion AO −
CD complex.
Figure 4. (A) Schematic representation of chemical structure of CDs, showing primary and secondary -OH groups and their
conformation (truncate shape). (B) Inclusion complex for gallates (stoichiometry 1:1) with the phenolic ring inserted into
the CD cavity and the -OH groups pointing outwards. (C) Representation of potential distributions of a free hydrophilic
CD, gallates, and a gallates–CD complex between bulk water, unstirred water, and membrane. Gallates–CD complex
formation can enchance gallates diffusion through the unstirred water phase and, consequently, their membrane permeation
(adapted from reference [169]. (D) Schematic representation of potential localization of a free AO and AO − CD complex
in liposomes.
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6.1.1. Cyclodextrin Complexation with Antioxidants
CDs can encapsulate poorly water-soluble polyphenols, not only to improve their
solubility, but also to protect them from side-effects of their environmental conditions (light,
temperature, pH, etc.). The formation of inclusion complexes with CDs has been observed
with a variety of antioxidants, including rosmarinic acid [171,172], ferulic acid [173], and
gallic acid [15,174], as well as resveratrol [175], quercetin [176], tea polyphenols, [177] and
phenol-rich plant extracts [15], among others. Here, the complexation of antioxidants with
CDs leads to enhanced water solubility of free compounds, as well as increased stability,
bioavailability, and in vitro antioxidant activity. In this sense, García-Pérez et al. [178]
showed that the value of the concentration of gallates required to reduce the DPPH•
radical concentration by 50% (%Inhibition = 50%, EC50 value) decreased by ~1.3–1.5 fold
when they were encapsulated in CDs, Table 6. Yallapu et al. [179] prepared a β-CD based
curcumin drug delivery carrier and showed that β-CD-curcumin enhanced the distribution
of curcumin in prostate cancer cells when compared to free curcumin, increasing its
therapeutic activity.
Table 6. Inclusion constants KAO for gallates and values of the concentration of gallates required to
reduce the DPPH• radical concentration by 50% (EC50 value) [178].
AO KAO (M−1) 105 EC50 (M)
β-CD HP-β-CD 0 M β-CD 11 mM β-CD
Gallic acid - 551 6.5 ± 0.1 5.8 ± 0.1
Methyl gallate - 595
Ethyl gallate - 380
Propyl gallate
(PG)
125 ± 11 a
105 ± 2 b
343 ± 9 a
328 ± 7 b 5.7 ± 0.1 3.9 ± 0.1
Butyl gallate
(BG)
198 ± 13 a
200 ± 15 b 706 ± 38
a 5.2 ± 0.3 4.1 ± 0.2
Octyl gallate
(OG) 4810 ± 98
b 5.7 ± 0.1 4.1 ± 0.1
Values from reference [32] obtained by a UV shift method, b phase-solubility method (buffered aqueous solution
with citric acid-sodium citrate 0.04 M, pH 3.65).
CDs can modify AO’s permeability through biological membranes under certain
medium conditions, when the contribution of an unstirred aqueous phase to the overall
barrier function of a membrane is significant and it becomes the rate limiting step in the
absorption process for a poorly water soluble AO [180]. So, hydrophilic AO − CD complex
formation can regulate AO flux though membranes, based on their interactions with the
unstirred water phase that separates the bulk media from biological membranes, including
the cornea, reproductive tract, and the gastric mucosa, as seen in Figure 4C [180]. On
the other hand, observations also show that hydrophobic AO − CDs (e.g., methylated
CDs) enhance AO flux by changing membrane (e.g., in the nasal mucosa) properties [167].
CDs can form complexes with membrane components such as phospholipids, cholesterol,
or other lipophilic molecules, producing changes at a cellular level or within biological
barriers [167,170]. Besides, CD inclusion complexes can improve absorption by passing
p-glycoprotein (P-gp)-mediated efflux activity. P-gp is a transporter expressed in the
intestines, liver, kidney, etc., that promotes the efflux of guest molecules, which constitutes
a major absorption barrier [167,170]. These properties make them a helpful tool for the
development of new drug delivery systems.
6.1.2. Cyclodextrin-Based Nanocarriers of Antioxidants
The combination of CD complexation with nanotechnology represents a potential
approach regarding the development of multifunctional CD-based delivery nanocarriers to
address therapeutic needs [167]. So, the development of cyclodextrin-based compounds
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will likely be accelerated in the coming years, and involves the combination of two ap-
proaches in a single nanocarrier: (1) the formation of AO − CD complexes and (2) the
encapsulation of complexed AO into a delivery system.
The currently used cyclodextrin-based nanocarrier of AOs can enhance their bioavail-
ability, extend the existence of AO in systemic circulation, decrease its toxicity, and has a
proven controlled release, addressing some drawbacks linked with each individual system
(that can reduce the CD’s effectiveness, as delivery systems have a fast elimination from the
bloodstream after their in vivo administration, or a potential substitution of the encapsu-
lated AO by other molecules with higher affinity for the inner CD cavity may occur) [181].
Some of the cyclodextrin-based carriers of AOs include liposomes, nioxomes, nanosponges,
micelles, polymeric millirods, and magnetic nanoparticles, among others [181]. For exam-
ple, liposomes in the presence of CDs have demonstrated to be a promising delivery system
for enhancing the entrapment activity and stability of antioxidants such as curcumin, as
seen in Figure 4D. CD–resveratrol nanoparticles showed an improved therapeutic efficiency
when compared to free resveratrol by passive targeting, while maintaining its antioxidant
effects [182]. CDs are also known to enhance quercetin’s permeation through biological
membranes. In this way, to increase quercetin’s brain uptake, nasal powders composed
of quercetin-cyclodextrin lyophilizates, mixed with spray-dried microparticles of manni-
tol/lecithin, were formulated, increasing their solubility 19–35 times when complexed with
cyclodextrins [183]. In this way, the employment of AO delivery systems has focused on
the combination of colloidal vesicles and CDs, constituting a promising strategy to find an
effective therapy with the least possible side effects.
6.2. Microemulsions
Microemulsions are self-assembled colloidal systems that are formulated from oil,
water, a surfactant, and a cosurfactant. They are thermodynamically stable and transparent
mixtures, with droplet sizes between 10 and 100 nm [184]. In microemulsions, the stabiliza-
tion of the droplets is provided by the reduction of the interfacial tension between the two
phases via the surfactant and cosurfactant.
Microemulsions are one of the most preferable delivery systems because of the sim-
plicity of their preparation process. Hydrophilic and lipophilic substances can be loaded in
different phases of microemulsions with a high encapsulation efficiency, and they can be
administered as liquid forms. They provide a controlled release and improve the stability of
encapsulated cargo against hydrolysis and oxidation [185]. It is known that microemulsions
resist gravitational collapse due to their small droplet size. Various factors affect the droplet
size in microemulsion systems, including the alkyl chain length of the oil, the surfactant
type, and the rigidity of the interfacial film. The nanodroplet size improves the absorption
and bioavailability of the substances by increasing the surface area to volume ratio [186].
Different classes of surfactants are used to prepare microemulsions. The uncharged struc-
ture, stability against pH changes, and safety profile make non-ionic surfactants (such
as Tweens, Spans, Brij, Pluronics, etc.) more advantageous. The cosurfactants (such as
alcohols, glycerol derivatives, polyglycerols, etc.) are used to further reduce the interfacial
tension and provide flexibility to the interfacial film. The assembly of microemulsions
is possible because the interfacial tension between the immiscible phases reach close to
zero. This is explained by several approaches, including film theory, solubilization the-
ory, and thermodynamic theory [187]. The interfacial free energy should be reduced to
facilitate the formation of microemulsions [188]. The thermodynamics of microemulsions
can be explained by the Equation (2), where DG f stands for the free energy of formation,
γ: Surface tension of the oil–water interface; DA: The change in the interfacial area on
microemulsification, DS: The change in entropy of the system, and T: Temperature.
DG f = γDA− TDS (2)
The phase titration and phase inversion are the main microemulsion production
methods [189]. Microemulsion formulations (Figure 5) are designed to deliver polyphe-
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nols by a wide range of administration routes, including oral, parenteral, transdermal,
nasal, etc. [187].
Figure 5. Schematic representation of the droplet structure of an oil-in-water microemulsion carrying
polyphenolic agents.
Encapsulation of curcumin into O/W and W/O/W microemulsions (droplet size
10–20 nm) improved its solubility, stability, and antioxidant capacity. The position of
curcumin within the inner structure of microemulsions was confirmed by 1H NMR stud-
ies [190]. Improved oral bioavailability (~2.5 times higher) was obtained after adminis-
tration of curcumin-loaded turmeric oil microemulsions, with a droplet size of 29 nm in
zebra fish. Besides, ex vivo drug permeation studies in the chicken gut sac also revealed
the enhancement of flux when compared to curcumin solution [191]. The hepatoprotective
activity of polyphenols-enriched fraction (Fr 1), extracted from Ajwa fruits, was shown in
cell culture and in vivo mice models. Fr 1-carrying microemulsions significantly improved
the oral bioavailability of the compound when compared to the suspension form [192]. The
solubility of quercetin was improved by microemulsions and the in situ studies revealed an
increased absorption percentage in different regions of rat intestine [193]. Overall studies
indicate that microemulsions can increase the oral bioavailability of compounds by paracel-
lular diffusion and lymphatic transport. They also contribute to the stability of molecules
by protecting against enzymatic degradation in the gastrointestinal tract [46,47].
Gallic acid microemulsions were shown to improve the antioxidant activity of the
compound [194]. Incorporation of chitosan to microemulsions further improved the trans-
port of gallic acid through RPMI 2650 cell lines (human nasal epithelial cell line) without
exhibiting any cytotoxic effects. Thus, this formulation was found promising for the nasal
delivery of antioxidants as an alternative to the oral route [195]. Brain-targeted delivery
of curcumin via the nasal route was successfully shown via microemulsion-based gel
formulations containing polycarbophil as a mucoadhesive agent [196].
Several factors potentialize the drug delivery to skin via microemulsions. The low
interfacial tension between the water and oil phases is thought to improve the contact to
skin. The excipients of microemulsions also act as penetration enhancers [197]. Topical
microemulsion formulations of catechin have improved the cumulative amount of the
transported drug through Sprag Dawley skin layers up to 111.6 fold, and shorten lag
times in in vitro experiments [198]. In vitro and in vivo skin penetration of quercetin was
increased via canola oil-based w/o microemulsions, and this was found to be effective
against UVB damage [199]. Efficient delivery of resveratrol to the dermis layer of the
Yucatan micropig (YMP) skin was obtained using an oil-in-water (o/w)-type microemulsion
containing sucrose laurate as a surfactant [200].
As mentioned, the superiority of polyphenol-containing microemulsions has been
demonstrated by various in vivo and in vitro studies. However, some considerations
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should be taken into account when using these systems. As high concentrations of surfac-
tants and co-surfactants are required to stabilize the nanosized droplets of microemulsions,
they should be investigated in terms of their potential toxicity. Environmental parame-
ters, such as temperature and pH, may lead to stability problems such as “breaking” and
“phase separation” [40].
6.3. Emulsions and Nanoemulsions
Emulsions and nanoemulsions are thermodynamically unstable mixtures of two
immiscible liquids (oil and water), one dispersed as droplets throughout the other one
(continuous phase), that can be stabilized kinetically by the addition of surfactants and
co-surfactants that form an interfacial region, separating the oil from the aqueous solution,
as seen in Scheme 8 [201]. The main difference between nanoemulsions and emulsions is
the size of the droplets in the system. Although there is not a clear separation, nanoemul-
sions are considered to have droplets with diameters lower than 200 nm. Nevertheless,
nanoemulsions have some physicochemical properties that are distinct from those of emul-
sions: they can be optically clear, due to the limited light scattering by small droplets; they
can be highly stable against gravitational separation, due to weak gravitational forces and
Brownian motion effects, and they may present higher bioavailability.
Scheme 8. Oil-in-water emulsions and nanoemulsions contain three-dimensional regions (oil, inter-
facial, and aqueous) where antioxidants can be located. A small portion of the regions is displayed
in the right picture, showing the chemical structure of a surfactant and the potential locations of an
antioxidant. The interfacial region is the main reaction site where the inhibition reaction between
antioxidants and lipid radicals takes place [39,178].
When compared with emulsions, the emulsifier concentration used is usually critical,
and plays a role in stabilizing droplets through both repulsive electrostatic forces and steric
hindrance. Although surfactants are usually used as emulsifiers, both proteins and lipids
can also be used in the stabilization of emulsions and nanoemulsions [58].
Nanoemulsion preparation can be achieved basically by two methodologies, as seen
in Figure 6: by high-energy and by low-energy methods [1]. High-energy methods, namely
ultrasonication, high pressure homogenization (HPH), evaporative ripening [202], and
microfluidization, usually consume a significant amount of energy and require multiple
passes/steps in order to obtain the required droplet size [201]. In contrast, low-energy meth-
ods, such as phase inversion temperature (PIT) [203], emulsion inversion point (EIP) [204],
and bubble bursting at the oil/water interface [205], use specific material properties to
make small droplets without consuming a significant amount of energy.
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Figure 6. Common methods for preparing oil-in-water nanoemulsions. (A) The high energy methods, such as high pressure
homogenization (HPH) and ultrasonication, break coarse emulsions drops into smaller droplets. (B) The low-energy
methods start with W/O coarse emulsions, and droplets are broken into smaller droplets during the low interfacial
tension state that occurs during phase rans tion, induced by the water dilution. In the phase inversion te perature (PIT)
method, the phase inversion occurs by cooling the mixture. W/O nanoemulsions can be prepared by employing the
same methodology.
Nanoemulsions have a range of application fields, including hydrophobic drug de-
livery [202], in the bioaccessibility and digestibility improvement of some nutrients in the
gastrointestinal tract and skin, and can also be used in the preparation of more complex
particles, such as co partmentalized nanoparticles [202].
The physicochemical characteristics of a nanoemulsion are largely dependent on
the composition, physical state, size, aggregation state, electric charge, and interfacial
composition of droplets. In turn, the final droplet size can be influenced by the relative
viscosity (µd/µc) of the oil and aquouse phases, the emulsifier concentration ([S]), and
the emulsifier properties (thickness, charge, hydrophobicity, length, etc.) [206]. Moreover,
the droplet electric characteristics are largely determined by the nature of the surface-
active substances adsorbed to their surface, including the emusifier charge and the ionic
composition of the aquouese phase [206], which play a major role in determining the
physical and chemical stability of the nanoemulsion, its bioavalability, and the possibility of
it being used in the production of compartmentalized nanoparticles. The knowlege of these
parameteres permits us to tailor the properties of the nanoemulsion droplets, in order to
produce the required physicochemical or physiological properties for a specific application.
Typically, nanoemulsions contain a range of different droplet sizes, and therefore, their
dimensions are characterized in terms of size distribution, mean droplet diameter, and
polydispersity index. In contrast with conventional emulsions, in nanoemulsions, the
interfacial region can achieve an important droplet volume [207], as can be envisaged
from Equation (3), where ØS (=VS/VC+S) is the volume of the emulsifier (s) divided by the
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effective volume of the overall droplet (=core + s), δS is the thickness of the emulsifier, and
r is the radius of the oil droplet (core). Consequently, the choice of the best emulsifier is







The properties, formation and stability of nanoemulsions also depend on the bulk
physicochemical properties of the oil phase, namely their hydrosolubility, interfacial ten-
sion, viscosity, density, phase behavior, and chemical stability [207,208]. These properties
often limit the methodology that is able to be used in their prepration. For example, low
γ usually facilitates droplet formation both in phase-inversion and spontaneous emulsifi-
cation, as well as in high-energy methods, but it may lead to poor emulsifier affinity for
droplet surfaces, promoting droplet coalescence.
In the food industry, nanoemulsions are usually prepared using edible oils, due to their
low cost, and their functional and nutritional caracheteristics, such as olive, corn, soybean,
sunflower, flaxseed, and more recently, fish and algae oils. The major constituints of these
oils are long-chain triacylglycerols and, therefore, the preparation of nanoemulsions with
these oils is often difficult by the phase-inversion temperature (PIT) method, because of
their very high hydrophobicity, as well as by high-pressure homogenization methods,
because of their high viscosity [201,208]. However, once a nanoemulsion has been prepared
they are often highly physically stable. In contrast, other less common edible oils, such as
flavor and essential oils, with a relatively high polarity, low interfacial tension, and low
viscosity, can easily produce very small droplets by both methodologies but, once produced,
these nanoemulsions have a low stability because, due to their higher hydrosolubility
and lower interfacial tension, they suffer from Ostwald ripening or coalescence. Several
strategies can be used to prevent the low stability of nanoemulsions, and the interested
reader is referred to some reports [201,209]. Low-energy methodologies’ limitations also
include the impossibility of using proteins or polysaccharides as emulsifiers and the need of
a relatively high concentration of synthetic surfactants, which may hinder their application
in many foods.
Nanoemulsions can be used to design functional foods with ingredients that are diffi-
cult to incorporate, due to low water solubility. Lipophilic components are usually mixed
with the oil phase prior to nanoemulsion preparation, so that they end up trapped within
the oil core of droplets. For example, the bioaccessibility of the highly lipophilic molecule of
β-carotene, a pigment with important antioxidant and health benefits, can be improved by
being incorporated [207,210,211] in nanoemulsions prepared by different methods and with
different compounds, such as β-lactoglobulin, which is used as a biocompatible emulsifier.
Another antioxidant that is quite often incorporated into nanoemulsions because of its
easier digestion and higher bioassessibility is curcumin, an anti-inflammatory agent [212].
Oil-soluble vitamins [201] have also been incapsulated in nanoemulsions.
Consumption of fish oil rich in omega-3 polyunsaturated lipids and oil-soluble vi-
tamins is linked to improved human health, which has partly been attributed to their
important role in brain and cardiovascular health [206]. However, the use of this oil is a
major challenge, due to its low hydrosolubility, unpleasant fishy taste, bioavailability, and
its high susceptibility to oxidation, due to the high degree of lipid unsaturation. Emul-
sified systems have a high potential for overcoming some of these challenges since they
can be designed to have good kinetic stability, oral bioavailability, to mask undesirable
flavors [206], and can be used not only in parenteral nutrition but also to fortify beverages,
sauces, and desserts, or to increase the bioavalability of omega-3-FA formulations. The
lower oxidative stability of these preparations has hindered their application and safety.
Efforts to minimize the impact of omega-3 FA oxidation have increased in the last few years
by optimizing food processing, packaging and refrigeration [206]. However, controlled
storage can be expensive and time consuming. Thus, for economical and practical reasons,
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the addition of AOs is one of the best strategies that is employed in industry to retard
lipid oxidation.
One of the increasing areas of nanoemulsion applications is in dermatological products,
both in the treatment of skin pathologies and as anti-aging skincare, due to the effective pen-
etration of nano droplets onto the skin’s surface, their pleasant visual appearance, and their
stabilization of ingredients, including vitamins and antioxidants [201,213,214]. Because of
its tunable droplet size, nanoemulsions reported less skin irritation, due to the penetration
of droplets over skin via hair follicles and pores and not affecting healthy tissues [69–71].
There are several examples of nanoemulsion formulations with high bioactive transdermal
availability without degradation using flavanones, curcumin, resveratrol, quercetin, nari-
genin, and retinyl palmitate with efficient antioxidant and anti-aging activities [214–216].
The physical location of antioxidants within nanoemulsions depends on their molecu-
lar properties and solubility in the oil, aqueous, and interfacial region. Studies concerning
the location of antioxidants in emulsified systems has led to the important conclusion
that droplet size has a negligible effect on the distribution and effective concentration of
antioxidants (and probably of any other molecule) in the aqueous and interfacial regions
of the emulsion, as the partition constants of the molecules between the aqueous and
interfacial regions and between the oil phase and interfacial region do not change with
the size of the droplet [217–219]. Further details on the distribution of antioxidants in
emulsions and nanoemulsions are provided in the next section.
6.4. Antioxidant Distributions and Efficiencies in Emulsions and Nanoemulsions
Polyphenolic antioxidants and antimicrobials are added in different forms to con-
trol lipid oxidation and the growth of pathogenic and spoilage microorganisms [220].
Emulsions and nanoemulsions show great promise as antioxidant carriers in the nanoscale
dimension [18,50,221]. Their advantages include, among others, an improvement in the pro-
tection of the delivery system against oxidation of lipidic components, antimicrobial action
by improving intracellular penetration, and the delivery of required drugs to specific sites
by preparing tailored surfaces of the carriers, for instance, changing the nature of the oils
and of the emulsifiers employed to stabilize kinetically the nanoemulsions [18,50,221,222].
Fundamental questions that arise when using delivery systems include how the
polyphenols are distributed between the oil, water, and interfacial regions of the emulsions
and what are the real concentrations in each region. Linked to these basic questions,
others also arise concerning the effects of the environmental (e.g., acidity, temperature)
and formulation (type of oil, oil-to-water ratio, the surfactant employed etc.) conditions
on their partitioning and their efficiency. Indeed, the interfacial oil–water film plays a key
role because its solvent properties are different from those the bulk water and oil, and
antioxidants may accumulate in this region, affecting their efficiency [218,219,223–226].
Emulsions are mixtures of oil, water, and surfactant where either the water or the
oil can act as dispersing phase, leading to the formation of oil-in-water and water-in-
oil emulsions, respectively. Scheme 8 shows the droplets of an oil-in-water emulsion
and the conceptual division in three distinctive regions: the droplet core (oil), the con-
tinuous aqueous phase, and the three-dimensional interfacial region. The interfacial
region (composed of surface-active molecules, oil, water, and other components) is highly
anisotropic and comprises a narrow region (typically 2 to 20 nm thick), enclosing the
oily droplet core [18,50,227].
Studies on the effects of factors controlling the allocation of antioxidants in emulsions
(e.g., oil-to-water ratio, acidity, temperature, type of oil) indicate that the surfactant volume
fraction is the main parameter controlling their distribution, except the acidity of the solu-
tion for phenolic acids or vitamin C. Results on the distribution of antioxidants in emulsions
show, therefore, that: (i) the fraction of AOs in the interfacial regions of the emulsions do
not correlate directly with the hydrophobicity of the AO; and (ii) that the fraction of AO in
the interfacial region reaches a maximum for AO’s of intermediate polarity or intermediate
alkyl chain length. An optimal balance of hydrophobicity and hydrophilicity (headgroup
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polarity) is required for maximum solubility of the AO in the interfacial region of the
emulsion and, therefore, maximum antioxidant efficiency. Hence, the antioxidant and
antibacterial properties of the interfacial region can be improved by targeting antioxidants
to the interfaces of emulsions, where their local, effective, concentration is much higher
than the stoichiometric one [18,50,227].
Further research is, however, needed to achieve a better understanding on the location
and orientations of polyphenols in the interfaces of emulsion-based delivery systems.
This definitely will allow for an optimal control of the subsequent release of incorporated
bioactives in specific sites, allowing for the preparation of target-tailored systems and
increasing their efficiency in the biology, medical, pharmaceutical, and cosmetic areas.
Certainly, a deeper knowledge on the location and distribution of the bioactives in the
system will aid in the development of new delivery systems, not only as nutritional
supplements, but also with potential benefits to human health [8,15,47].
7. Concluding Remarks
This review aims to provide a general overview of the biological activity of polypheno-
lic antioxidants, and strategies to improve their bioavailability and thus, their efficiency, to
reduce or inhibit ROS damage. Some, but not all, of their therapeutic effects of polyphenolic
antioxidants are known but further both in vitro and in vivo (clinical) studies will help
to evaluate and fully understand their bioavailability, bioactivity, and to develop new
antioxidant strategies, including their delivery to target areas, in attempting to prevent
oxidative stress, minimizing damage to DNA, protein, cells, and other important molecules
and tissues, while maintaining the cellular redox homeostasis.
Oxidative stress is of key importance in the pathogenesis of many health diseases and
the use of exogenous antioxidants to improve the endogenous antioxidant system could be
used to reduce it. While there is a large body of research demonstrating the general effect
of oxidative stress on signaling pathways, little is known about the effects of AOs on the
cellular regulation of ROS, their bioavailability, and their bioactivity at the reaction sites.
Antioxidants need to be properly positioned (location and orientation) in compartmental-
ized systems to react efficiently with excesses of ROS and to protect biomolecules from
oxidative damage. In these systems, the biointerfaces are most probably the critical areas
where the inhibition reaction takes place, and studies about the delivering and partitioning
of antioxidants are critical to fully understand and optimize their performance. Certainly, a
better understanding of the mechanisms through which antioxidants act, and where and
when they are effective, may give a more rational strategy for extending food shelf-life
and the prevention of health diseases, and so will help to solve several limitations that
challenge the ability to therapeutically apply antioxidant strategies.
Dispensation of bioactives to humans is challenging because their delivery and release
into the surrounding medium needs to be controlled to improve their bioavailability. In
addition, the actual bioactive may need to be protected from the environment to maintain
its therapeutic properties. Research strategies and directions into the administration and
release of bioactives are mostly inspired by the modeling of biological systems. For example,
a nice model that inspired many researchers is based on the protective role of cell walls,
controlling the exchange of matter with the surrounding medium and sheltering the interior
components from the extracellular environment. Based on these observations, cyclodextrins
and colloidal systems such as emulsions, nanoemulsions, and microemulsions have a great
potential as delivery systems and, for example, are widely employed in parenteral nutrition
as energy sources and, at the same time, for the delivery of multiple nutrients.
In the last few years, lipid-based delivery systems have gained much attraction be-
cause they have a great potential in parenteral nutrition as energy sources and, at the
same time, for the delivery of multiple nutrients. Research on the encapsulation of antioxi-
dants has attracted great interest in the functional food, nutraceutical, and pharmaceutical
industries, due to their health benefits to humans. Certainly, the use of encapsulated
polyphenols, instead of free compounds, can effectively overcome solubility problems and,
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at the same time, preserve the stability, bioactivity, and bioavailability of the polyphenol. It
appears, therefore, of outmost importance to control the distribution and partitioning of
the bioactives (e.g., antioxidants), nevertheless, knowledge on how partitioning influences
their efficiency is challenging. Predicting bioactive distributions and gaining some control
on their partitioning is necessary for developing specific strategies to encapsulate and
deliver antioxidants.
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